The ADR was listed on 14th Nov 2024.
Very little info on prostate cancer therapeutics since than.
I asked AI to check:
Here’s what I found regarding Telix’s company announcements since its NASDAQ ADR listing (14 November 2024) that pertain specifically to prostate cancer therapeutic products (TLX591, TLX592):
---
1. Q4 FY2024 Business Update
Date: 6 months ago (around May/June 2025)
Content: Confirmed that ProstACT GLOBAL, the Phase III trial of TLX591 for PSMA-positive metastatic castrate-resistant prostate cancer, is progressing. First interim readout expected in H1 2025 . Though broader in scope, it clearly relates to the prostate cancer therapeutic program.
---
Therapeutic Data Announcements (May 2024)
These were prior to the ADR listing (pre-November 2024), so they don’t count toward your timeframe:
Positive rPFS data from ProstACT SELECT (TLX591) – 31 May 2024
Completion of proof-of-concept for TLX592 (CUPID) study – 20 May 2024
Those did not fall after November 2024, so they don’t count.
---
✅ Conclusion
Since the NASDAQ ADR began trading on 14 November 2024, only one company announcement concerning Telix’s prostate cancer therapeutic products has been released:
The Q4 FY24 Business Update confirming ongoing Phase III development of TLX591
No additional TLX591 or TLX592 study data or therapeutic results have been announced in that period.
---
So, I wonder what it is they are probing?
Incorrect info in the above announcements or not enough announcements? Have they been late to advise of a development?
(20min delay)